Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What is new in lymphoma?

Bruce D Cheson1

  • 1Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

CA: a Cancer Journal for Clinicians
|September 17, 2004
PubMed
Summary

Recent advances in lymphoma research have led to new therapies, including monoclonal antibodies like rituximab, improving patient outcomes. Ongoing clinical research aims to optimize these treatments for better lymphoma cure rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia.

JCO oncology practice·2024
Same author

Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease.

Clinical lymphoma, myeloma & leukemia·2024
Same author

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.

Blood advances·2024
Same author

Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.

Blood advances·2024
Same author

A man's best friend is his PET.

Blood·2023

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Lymphomas are diverse malignant disorders with varying molecular features and clinical presentations.
  • Recent advancements have improved understanding of lymphoma biology, leading to updated classification systems.
  • New therapies and prognostic tools enhance treatment strategies and clinical trial interpretability.

Purpose of the Study:

  • To summarize recent advances in lymphoma understanding and treatment.
  • To highlight novel therapeutic agents and their potential impact on patient outcomes.
  • To discuss the challenges and future directions in lymphoma clinical research.

Main Methods:

  • Review of current literature on lymphoma biology and therapeutics.
  • Analysis of novel agents including monoclonal antibodies, radioimmunoconjugates, and chemotherapy regimens.
  • Discussion of prognostic indices and response criteria in clinical trials.

Main Results:

  • The chimeric anti-CD20 monoclonal antibody rituximab has significantly impacted B-cell disorder treatment.
  • Various novel agents like radioimmunoconjugates and BCL-2 antisense oligonucleotides show promise.
  • New chemotherapy regimens (e.g., BEACOPP) and targeted antibodies are under investigation for Hodgkin Lymphoma.

Conclusions:

  • Novel therapies, including rituximab and other targeted agents, are transforming lymphoma treatment paradigms.
  • Optimizing the use of these agents and developing multitargeted strategies are crucial for increasing cure rates.
  • Continued clinical research is essential to refine treatment protocols and improve patient outcomes in lymphomas.

Related Experiment Videos